Former Director of the Drug Evaluation Center of the State Food and Drug Administration: Drug R&D reform should combine five major technologies including blockchain

Xu Jiaqi, former director of the Drug Evaluation Center (CDE) of the State Drug Administration, said recently that the current innovative drug development model is in urgent need of reform. Xu Jiaqi believes that the reform of drug research and development should fully integrate the current five major technologies – ABCD + 5G. A is artificial intelligence, B stands for blockchain, C is cloud computing, and D is big data. For example, after using the above-mentioned emerging technologies to solve the delivery system (DDS), China's hepatitis B is entirely likely to find new drugs like hepatitis C to achieve a functional cure for hepatitis B.